Bioleap

Revolutionising Immunotherapy Development with Precision Biosimulation. At Bioleap, we are transforming the way immunotherapies are developed. By combining cutting-edge mechanistic modelling with the power of AI, our proprietary Hybrid-AI biosimulation platform delivers unprecedented predictive accuracy—100x greater than traditional methods—and accelerates development timelines by reducing data requirements by 20-fold. Our mission is to empower therapy developers with actionable insights that drive success at every stage of the development pipeline. From discovery to clinical trials, Bioleap’s technology simulates thousands of scenarios to optimise patient stratification, refine dosing strategies, and predict outcomes for complex therapies, including CAR-T and TCR-T. Bioleap is not just advancing science; we are building partnerships that unlock new possibilities in immunotherapy. Whether you’re looking to accelerate preclinical research, improve clinical trial outcomes, or enhance therapeutic precision, Bioleap is your trusted partner in the journey to delivering life-changing therapies. Interested in learning more or partnering with us? Visit www.bioleap.ai or get in touch today.